ArticleFuture science OA2018
Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis.
Enrique R Soriano et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papertrialcites it